2. Academic Validation
  3. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

  • Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360-5. doi: 10.1073/pnas.1210371110.
Wei Qi 1,  HoMan Chan,  Lin Teng,  Ling Li,  Shannon Chuai,  Ruipeng Zhang,  Jue Zeng,  Min Li,  Hong Fan,  Ying Lin,  Justin Gu,  Ophelia Ardayfio,  Ji-Hu Zhang,  Xiaoxia Yan,  Jialuo Fang,  Yuan Mi,  Man Zhang,  Tao Zhou,  Grace Feng,  Zijun Chen,  Guobin Li,  Teddy Yang,  Kehao Zhao,  Xianghui Liu,  Zhengtian Yu,  Chris X Lu,  Peter Atadja,  En Li
Affiliations

Affiliation

  • 1 China Novartis Institutes for BioMedical Research, Shanghai 201203, China.
PMID: 23236167 DOI: 10.1073/pnas.1210371110
Abstract

EZH2 (Enhancer of zeste homolog 2) protein is the enzymatic component of the Polycomb repressive complex 2 (PRC2), which represses gene expression by methylating lysine 27 of histone H3 (H3K27) and regulates cell proliferation and differentiation during embryonic development. Recently, hot-spot mutations of EZH2 were identified in diffused large B-cell lymphomas and follicular lymphomas. To investigate if tumor growth is dependent on the enzymatic activity of EZH2, we developed a potent and selective small molecule inhibitor, EI1, which inhibits the enzymatic activity of EZH2 through direct binding to the Enzyme and competing with the methyl group donor S-Adenosyl methionine. EI1-treated cells exhibit genome-wide loss of H3K27 methylation and activation of PRC2 target genes. Furthermore, inhibition of EZH2 by EI1 in diffused large B-cell lymphomas cells carrying the Y641 mutations results in decreased proliferation, cell cycle arrest, and Apoptosis. These results provide strong validation of EZH2 as a potential therapeutic target for the treatment of Cancer.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z